NCT05369390View on ClinicalTrials.gov

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity

PHASE1CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

May 11, 2022

Primary Completion Date

January 9, 2024

Study Completion Date

January 9, 2024

Conditions
Obesity
Interventions
DRUG

NNC0487-0111 A

Participants will receive NNC0487-0111 A tablet once daily.

DRUG

NNC0487-0111 B

Participants will receive NNC0487-0111 B tablet once daily.

OTHER

Placebo B (NNC0487-0111 B)

Participants will receive placebo matched to NNC0487-0111 B tablet once daily.

OTHER

Placebo A (NNC0487-0111 A)

Participants will receive placebo matched to NNC0487-0111 A tablet once daily.

Trial Locations (2)

78209

ICON Early Phase Services, LLC, San Antonio

Novo Nordisk Investigational Site, San Antonio

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT05369390 - A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity | Biotech Hunter | Biotech Hunter